A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

NCT02533453 · Completed

Last updated 2026-05-28

This study tests the safety of a once-weekly 2mg dose of exenatide (Bydureon) in adults with type 2 diabetes over 12 or 24 weeks.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 110 people

Who can join Ages 19–75 · all sexes

Timeline Started 2016-01 · est. completion 2016-12

Where 15 sites · South Korea

What this study is testing ClinicalTrials.gov NCT02533453 ↗

Description as written by the study sponsor.

As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is used.

Treatments tested

Bydureon also known as exenatide Biologic

exenatide once weekly

Main thing measured	Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02533453 ↗